The CEO foresees a "snowball effect" of life sciences companies coming to Dallas, but a couple things need to happen first.

BioLizard has supported the development of novel biomarker programs, contributed to AI-driven drug discovery efforts, and ...

Michael Breen, CEO of GT Biopharma, said current cancer treatments are 80 years old.

In the northwest corner of Sioux Falls, an 80-acre campus opened its first building this year dedicated entirely to expanding ...

Is a new obesity drug making people lose too much weight? Plus catch up on #ASH25 and hear how the country's scientific ...

The actor narrates a new documentary that expresses skepticism toward vaccines and includes discredited science ...

Students of Guru Gobind Singh Indraprastha University will now benefit from expanded research opportunities, hands-on ...

When visionary entrepreneur and investor David Roja joined The Rhonda Swan Show: Wake Up New York City Edition on Wall Street ...

Investors and young scientists are pulling back from biotech, amid broader attacks on science under Trump, industry ...

The biotech sector has been a disaster for investors over the past five years going by a 14% decline compared to an 86% gain ...

AI powers digital twins of cells/molecules, speeding early drug discovery and cutting trial-and-error work. Read more here.

A Pfizer-backed biotech landed $120M, embattled Kala Bio has secured a new CEO, and Akebia Therapeutics bought a rare kidney ...